Cite

HARVARD Citation

    El Dika, I. et al. (2020). Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer medicine. pp. 7453-7459. [Online]. 
  
Back to record